Publications by Sylvie Chevret

  • Moatti M, Chevret S, Zohar S, Rosenberger WF. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. Methods Inf Med. 2016 Jan 8;55(1):4-13. doi: 10.3414/ME14-01-0132. Epub 2015 Sep 25.
  • Darmon M, Vincent F, Canet E, Mokart D, Pène F, Kouatchet A, Mayaux J, Nyunga M, Bruneel F, Rabbat A, Lebert C, Perez P, Renault A, Meert AP, Benoit D, Hamidfar R, Jourdain M, Schlemmer B, Chevret S, Lemiale V, Azoulay E. Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologie. Nephrol Dial Transplant. 2015 Dec;30(12):2006-13. doi: 10.1093/ndt/gfv372.
  • Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? Eur J Cancer. 2015 Dec 24;54:69-74. doi: 10.1016/j.ejca.2015.11.017.
  • Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol. 2015 Dec 17. pii: mdv616
  • Lemiale V, Resche-Rigon M, Mokart D, Pène F, Rabbat A, Kouatchet A, Vincent F, Bruneel F, Nyunga M, Lebert C, Perez P, Meert AP, Benoit D, Chevret S, Azoulay E.Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study. Ann Intensive Care. 2015 Dec;5(1):28. doi: 10.1186/s13613-015-0070-z. Epub 2015 Sep 30.
  • Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F, Chevret S, Lejeune J, Raimbault A, Stamatoullas A, Rose C, Beyne-Rauzy O, Delaunay J, Solary E, Fenaux P, Dreyfus F, Preudhomme C, Kosmider O, Fontenay M. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood. 2015 Dec 1. pii: blood-2015-04-640128.
  • Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J, Faucher E, Nyunga M, Girault C, Perez P, Guitton C, Ekpe K, Kouatchet A, Théodose I, Benoit D, Canet E, Barbier F, Rabbat A, Bruneel F, Vincent F, Klouche K, Loay K, Mariotte E, Bouadma L, Moreau AS, Seguin A, Meert AP, Reignier J, Papazian L, Mehzari I, Cohen Y, Schenck M, Hamidfar R, Darmon M, Demoule A, Chevret S, Azoulay E; Groupe de Recherche en Réanimation Respiratoire du patient d’Onco-Hématologie (GRRR-OH). Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial. JAMA. 2015 Oct 27;314(16):1711-9.doi: 10.1001/jama.2015.12402.
  • Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Makhoul PC, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F. Lenalidomide with or without erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5q deletion.Leukemia. 2015 Oct 26. doi: 10.1038/leu.2015.296
  • Demoule A, Chevret S, Carlucci A, Kouatchet A, Jaber S, Meziani F, Schmidt M, Schnell D, Clergue C, Aboab J, Rabbat A, Eon B, Guérin C, Georges H, Zuber B, Dellamonica J, Das V, Cousson J, Perez D, Brochard L, Azoulay E; Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. oVNI Study Group; REVA Network (Research Network in Mechanical Ventilation). Intensive Care Med. 2015 Oct 13.
  • Moatti M, Chevret S, Zohar S, Rosenberger WF. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. Methods Inf Med. 2015 Sep 25;54(5).
  • Senéjoux A, Siproudhis L, Abramowitz L, Munoz Bongrand N, Desseaux K, Bouguen G, Bourreille A, Dewit O, Stefanescu C, Vernier G, Louis E, Grimaud JC, Godart B, Savoye G, Hebuterne X, Bauer P, Nachury M, Laharie D, Chevret S, Bouhnik Y. Fistula plug in fistulising ano-perineal Crohn's disease: a randomized controlled trial. J Crohns Colitis. 2015 Sep 8. pii: jjv162.
  • Hannouche D, Devriese F, Delambre J, Zadegan F, Tourabaly I, Sedel L, Chevret S, Nizard R. Ceramic-on-ceramic THA Implants in Patients Younger Than 20 Years. Clin Orthop Relat Res. 2015 Sep 4
  • Ecotière L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Goujon JM, Fermand JP, Touchard G, Bridoux F. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2015 Aug 19. pii: gfv283.
  • Biau DJ, Porcher R, Roren A, Babinet A, Rosencher N, Chevret S, Poiraudeau S, Anract P.Neither pre-operative education or a minimally invasive procedure have any influence on the recovery time after total hip replacement. Int Orthop. 2015 Aug;39(8):1475-81. doi: 10.1007/s00264-015-2802-y. Epub 2015 May 15.
  • Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roosweil D, Frenzel L, Tamburini J, Macro M, Chevret S, Avet-Loiseau H, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis. Haematologica. 2015 Jul 23. pii: haematol.2015.127001.
  • Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, Knebelmann B, Jaccard A, Chevret S, Touchard G, Fermand JP, Arnulf B, Bridoux F. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int. 2015 Jul 15. doi: 10.1038/ki.2015.201.
  • Lengliné E, Chevret S, Moreau AS, Pène F, Blot F, Bourhis JH, Buzyn A, Schlemmer B, Socié G, Azoulay E. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Jun;50(6):840-5. doi: 10.1038/bmt.2015.55
  • Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, Dominique S, de Revel T, Juvin K, Maillard N, Reman O, Contentin N, Robin M, Buzyn A, Socié G, Tazi A. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015 Jun 1;191(11):1242-9.
  • Dumas G, Géri G, Montlahuc C, Chemam S, Dangers L, Pichereau C, Brechot N, Duprey M, Mayaux J, Schenck M, Boisramé-Helms J, Thomas G, Baboi L, Mouthon L, Amoura Z, Papo T, Mahr A, Chevret S, Chiche JD, Azoulay E.Outcomes in Critically Ill Patients with Systemic Rheumatic Disease: a multicenter study. Chest. 2015 May 21. doi: 10.1378/chest.14-3098.
  • Kentish-Barnes N, Chaize M, Seegers V, Legriel S, Cariou A, Jaber S, Lefrant JY, Floccard B, Renault A, Vinatier I, Mathonnet A, Reuter D, Guisset O, Cohen-Solal Z, Cracco C, Seguin A, Durand-Gasselin J, Éon B, Thirion M, Rigaud JP, Philippon-Jouve B, Argaud L, Chouquer R, Adda M, Dedrie C, Georges H, Lebas E, Rolin N, Bollaert PE, Lecuyer L, Viquesnel G, Léone M, Chalumeau-Lemoine L, Garrouste M, Schlemmer B, Chevret S, Falissard B, Azoulay É. Complicated grief after death of a relative in the intensive care unit. Eur Respir J. 2015 May;45(5):1341-52. doi: 10.1183/09031936.00160014.
  • Caruana E, Chevret S, Resche-Rigon M, Pirracchio R. A new weighted balance measure helped to select the variables to be included in a propensity score model. J Clin Epidemiol. 2015 May 1. pii: S0895-4356(15)00212-7. doi: 10.1016/j.jclinepi.2015.04.009.
  • Kentish-Barnes N, Chaize M, Seegers V, Legriel S, Cariou A, Jaber S, Lefrant JY, Floccard B, Renault A, Vinatier I, Mathonnet A, Reuter D, Guisset O, Cohen-Solal Z, Cracco C, Seguin A, Durand-Gasselin J, Éon B, Thirion M, Rigaud JP, Philippon-Jouve B, Argaud L, Chouquer R, Adda M, Dedrie C, Georges H, Lebas E, Rolin N, Bollaert PE, Lecuyer L, Viquesnel G, Léone M, Chalumeau-Lemoine L, Garrouste M, Schlemmer B, Chevret S, Falissard B, Azoulay É. Complicated grief after death of a relative in the intensive care unit. Eur Respir J. 2015 May;45(5):1341-52. doi: 10.1183/ 09031936.00160014
  • Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lhéritier V, Chevret S, Ifrah N, Dombret H. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015 Apr 15. pii: blood-2015-02-627935.
  • Feghoul L, Chevret S, Cuinet A, Dalle JH, Ouachée M, Yacouben K, Fahd M, Guérin-El Khourouj V, Roupret-Serzec J, Sterkers G, Baruchel A, Simon F, LeGoff J. Adenovirus Infection and Disease in Pediatric Hematopoietic Stem Cell Transplant Patients: Clues for Antiviral Preemptive Treatment. Clin Microbiol Infect. 2015 Apr 13. pii: S1198-743X(15)00375-4. doi: 10.1016
  • Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. Cancer. 2015 Apr 6. doi: 10.1002/cncr.29389.
  • Bergeron A, Chevret S, Chagnon K, Godet C, Bergot E, Peffault de Latour R, Dominique S, de Revel T, Juvin K, Maillard N, Reman O, Contentin N, Robin M, Buzyn A, Socié G, Tazi A. Budesonide/Formoterol for Bronchiolitis Obliterans After Hematopoietic Stem Cell Transplantation. Am J Respir Crit Care Med. 2015 Apr 2.
  • Lengliné E, Chevret S, Moreau AS, Pène F, Blot F, Bourhis JH, Buzyn A, Schlemmer B, Socié G, Azoulay E. Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038
  • Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015
  • Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology. 2015 Feb 11. doi: 10.1002
  • Mokart D, Darmon M, Resche-Rigon M, Lemiale V, Pène F, Mayaux J, Rabbat A, Kouatchet A, Vincent F, Nyunga M, Bruneel F, Lebert C, Perez P, Renault A, Hamidfar R, Jourdain M, Meert AP, Benoit D, Chevret S, Azoulay E. Prognosis of neutropenic patients admitted to the intensive care unit. Intensive Care Med. 2015 Feb;41(2):296-303.
  • Chevret S, Seaman S, Resche-Rigon M. Multiple imputation: a mature approach to dealing with missing data. Intensive Care Med. 2015 Feb;41(2):348-50. doi: 10.1007/s00134-014-3624-x
  • Pirracchio R, Petersen ML, Carone M, Rigon MR, Chevret S, van der Laan MJ. Mortality prediction in intensive care units with the Super ICU Learner Algorithm (SICULA): a population-based study. Lancet Respir Med. 2015 Jan;3(1):42-52. doi: 10.1016/S2213-2600(14)70239-5.
  • Kentish-Barnes N, Chaize M, Seegers V, Legriel S, Cariou A, Jaber S, Lefrant JY, Floccard B, Renault A, Vinatier I, Mathonnet A, Reuter D, Guisset O, Cohen-Solal Z, Cracco C, Seguin A, Durand-Gasselin J, Éon B, Thirion M, Rigaud JP, Philippon-Jouve B, Argaud L, Chouquer R, Adda M, Dedrie C, Georges H, Lebas E, Rolin N, Bollaert PE, Lecuyer L, Viquesnel G, Léone M, Chalumeau-Lemoine L, Garrouste M, Schlemmer B, Chevret S, Falissard B, Azoulay É. Complicated grief after death of a relative in the intensive care unit. Eur Respir J. 2015 Jan 22. pii: ERJ-01600-2014
  • Lapidus N, Chevret S, Resche-Rigon M. Assessing assay agreement estimation for multiple left-censored data: a multiple imputation approach. Stat Med. 2014 Dec 30;33(30):5298-309. doi: 10.1002/sim.6319.
  • Annane D, Orlikowski D, Chevret S. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev. 2014 Dec 13;12:CD001941. doi: 10.1002/14651858.CD001941
  • Pirracchio R, Petersen ML, Carone M, Rigon MR, Chevret S, van der Laan MJ. Mortality prediction in intensive care units with the Super ICU Learner Algorithm (SICULA): a population-based study. Lancet Respir Med. 2014 Nov 24. pii: S2213-2600(14)70239-5. doi: 10.1016/S2213-2600(14)70239-5.
  • Rio B, Chevret S, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socie G, Ceballos P, Huynh A, Cornillon J, Françoise S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Gluckman E, Ruggeri A, Buzyn A, Nguyen S, Simon T, Milpied N, Rocha V; Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and Eurocord. Decreased non-relapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced intensity conditioning: a prospective phase-II multicentric trial. Biol Blood Marrow Transplant. 2014 Nov 18. pii: S1083-8791(14)00681-8. doi: 10.1016/j.bbmt.2014.11.009.
  • Pibouleau L, Chevret S. AN INTERNET-BASED METHOD TO ELICIT EXPERTS' BELIEFS FOR BAYESIAN PRIORS: A CASE STUDY IN INTRACRANIAL STENT EVALUATION. Int J Technol Assess Health Care. 2014 Nov 17:1-8.
  • Schlemmer F, Chevret S, Lorillon G, De Bazelaire C, Peffault de Latour R, Meignin V, Michallet M, Hermet E, Wyplosz B, Houdouin V, Marchand-Adam S, Socié G, Tazi A, Bergeron A. Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. Respir Med. 2014 Oct;108(10):1525-33. doi: 10.1016/j.rmed.2014.09.006. Epub 2014 Sep 16.
  • Lapidus N, Chevret S, Resche-Rigon M. Assessing assay agreement estimation for multiple left-censored data: a multiple imputation approach. Stat Med. 2014 Oct 8. doi: 10.1002/sim.6319.
  • Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, Plessier A, Roulot D, Chaffaut C, Bourcier V, Trinchet JC, Valla D; on behalf of Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2014 Oct 6. doi: 10.1002/hep.27546.
  • Lemiale V, Lambert J, Canet E, Mokart D, Pène F, Rabbat A, Kouatchet A, Vincent F, Bruneel F, Gruson D, Chevret S, Azoulay E; Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. Identifying cancer subjects with acute respiratory failure at high risk for intubation and mechanical ventilation. Respir Care. 2014 Oct;59(10):1517-23.
  • Schlemmer F, Chevret S, Lorillon G, De Bazelaire C, Peffault de Latour R, Meignin V, Michallet M, Hermet E, Wyplosz B, Houdouin V, Marchand-Adam S, Socié G, Tazi A, Bergeron A. Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. Respir Med. 2014 Sep 16. pii: S0954-6111(14)00317-5.
  • Pibouleau L, Chevret S. An internet-based method to elicit experts’ beliefs for Bayesian priors. International Journal of Technology Assessment in Health Care (in press)
  • Bige N, Zafrani L, Lambert J, Peraldi MN, Snanoudj R, Reuter D, Legendre C, Chevret S, Lemiale V, Schlemmer B, Azoulay E, Canet E. Severe infections requiring intensive care unit admission in kidney transplant recipients: impact on graft outcome. Transpl Infect Dis. 2014 Aug;16(4):588-96.
  • Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 2014 Aug 30;5(15):6280-8.
  • Chevret S. Propensity-matching analysis is not straightforward. Am J Respir Crit Care Med. 2014 Aug 15;190(4):362-4
  • Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 Aug;15(9):986-96.
  • Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Grardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cavé H, Chevallier P, Buzyn A, Fest T, Reman O, Vernant JP, Lhéritier V, Béné MC, Lafage M, Macintyre E, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014 Jun 12;123(24):3739-49.
  • Constant AL, Montlahuc C, Grimaldi D, Pichon N, Mongardon N, Bordenave L, Soummer A, Sauneuf B, Ricome S, Misset B, Schnell D, Dubuisson E, Brunet J, Lasocki S, Cronier P, Bouhemad B, Loriferne JF, Begot E, Vandenbunder B, Dhonneur G, Bedos JP, Jullien P, Resche-Rigon M, Legriel S. Predictors of Functional Outcome after Intraoperative Cardiac Arrest. Anesthesiology. 2014 May 16.
  • Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Grardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cavé H, Chevallier P, Buzyn A, Fest T, Reman O, Vernant JP, Lhéritier V, Béné MC, Lafage M, Macintyre E, Ifrah N, Dombret H. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014 Apr 16.
  • Annane D,. Chevret S Mortality in patients with hypovolemic shock treated with colloids or crystalloids--reply. JAMA. 2014 Mar 12;311(10):1069-70.
  • Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget. 2014 Feb 28;5(4):916-32.
  • Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget. 2014 Jan 20.
  • Lambert J, Chevret S. Summary measure of discrimination in survival models based on cumulative/dynamic time-dependent ROC curves. Stat Methods Med Res. 2014 Jan 5.
  • Sarkozy C, Terré C, Jardin F, Radford I, Roche-Lestienne C, Penther D, Bastard C, Rigaudeau S, Pilorge S, Morschhauser F, Bouscary D, Delarue R, Farhat H, Rousselot P, Hermine O, Tilly H, Chevret S, Castaigne S. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer. 2014 Jan;53(1):106-16.
  • Pirracchio R, Parenica J, Resche Rigon M, Chevret S, Spinar J, Jarkovsky J, Zannad F, Alla F, Mebazaa A; for the GREAT network. Correction: The Effectiveness of Inodilators in Reducing Short Term Mortality among Patient with Severe Cardiogenic Shock: A Propensity-Based Analysis. PLoS One. 2013 Dec 10;8(12).
  • Crenn P, Neveux N, Chevret S, Jaffray P, Cynober L, Melchior JC, Annane D; for the COIITSS Study Group. Plasma l-citrulline concentrations and its relationship with inflammation at the onset of septic shock: A pilot study. J Crit Care. 2013 Nov 26. pii: S0883-9441(13)00452-8.
  • Pirracchio R, Carone M, Rigon MR, Caruana E, Mebazaa A, Chevret S. Propensity score estimators for the average treatment effect and the average treatment effect on the treated may yield very different estimates. Stat Methods Med Res. 2013 Nov 6.
  • Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declère AD, Preiser JC, Outin H, Troché G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Régnier J, Abroug F, Berger P, Clec'h C, Cousson J, Thibault L, Chevret S; CRISTAL Investigators. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA. 2013 Nov 6;310(17):1809-17
  • Pirracchio R, Parenica J, Resche Rigon M, Chevret S, Spinar J, Jarkovsky J, Zannad F, Alla F, Mebazaa A; GREAT network. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One. 2013 Aug 15;8(8):e71659
  • Moatti M, Zohar S, Facon T, Moreau P, Mary JY, Chevret S. Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. Clin Trials. 2013 Jul 2.
  • Kant A, Gupta PK, Zohar S, Chevret S, Hopkins PM. Application of the Continual Reassessment Method to Dose-finding Studies in Regional Anesthesia: An Estimate of the ED95 Dose for 0.5% Bupivacaine for Ultrasound-guided Supraclavicular Block. Anesthesiology. 2013 Jul;119(1):29-35.
  • Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lassalle P, Charnaux N, Delehedde M, Sutton A, Nahon P. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev. 2013 Jun 18.
  • Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM, Rabbat A, Lebert C, Perez P, Chaize M, Renault A, Meert AP, Benoit D, Hamidfar R, Jourdain M, Darmon M, Schlemmer B, Chevret S, Lemiale V. Outcomes of Critically Ill Patients With Hematologic Malignancies: Prospective Multicenter Data From France and Belgium--A Groupe de Recherche Respiratoire en Reanimation Onco-Hematologique Study. J Clin Oncol. 2013 Jun 10.
  • Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, Thomas X, Quesnel B, Celli-Lebras K, Preudhomme C, Terré C, Fenaux P, Chevret S, Castaigne S, Dombret H. Outcome of older patients with acute myeloid leukemia (AML) in first relapse. Am J Hematol. 2013 Jun 8.
  • Brichler S, Le Gal F, Butt A, Chevret S, Gordien E. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol. 2013 Jun;11(6):734-40.
  • Pirracchio R, Resche-Rigon M, Chevret S, Journois D. Simple screening statistical tools to detect reporting bias: when should we ask for raw data? Crit Care. 2013 May 7;17(3):142.
  • Gupta PK, Chevret S, Zohar S, Hopkins PM. What is the ED95 of prilocaine for femoral nerve block using ultrasound? Br J Anaesth. 2013 May;110(5):831-6.
  • Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol. 2013 Apr 6.
  • H, Owen R, Lejeune J, Chevret S, Merle-Beral H, Leblond V. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia. Haematologica. 2013 Apr;98(4):649-54.
  • Pibouleau L, Chevret S. Bayesian hierarchical meta-analysis model for medical device evaluation: application to intracranial stents. Int J Technol Assess Health Care. 2013 Apr;29(2):123-30.
  • Nguyen-Khac F, Lambert J, Chapiro E, Grelier A, Mould S, Barin C, Daudignon A, Gachard N, Struski S, Henry C, Penther D, Mossafa H, Andrieux J, Eclache V, Bilhou-Nabera C, Luquet I, Terre C, Baranger L, Mugneret F, Chiesa J, Mozziconacci MJ, Callet-Bauchu E, Veronese L, Blons Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013 Mar 21;121(12):2213-23.
  • De Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kouatchet A, Lemiale V, Pène F, Bruneel F, Vincent F, Mayaux J, Chevret S, Azoulay E. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock. 2013 Mar;39(3):250-4.
  • Pham T, Combes A, Rozé H, Chevret S, Mercat A, Roch A, Mourvillier B, Ara-Somohano C, Bastien O, Zogheib E, Clavel M, Constan A, Marie Richard JC, Brun-Buisson C, Brochard L. Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2013 Feb 1;187(3):276-85.
  • Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, Patel S, Boutboul D, Marson MN, Gérard L, Lee M, Watier H, Oksenhendler E. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013 Feb;171(2):186-94.
  • Pirracchio R, Resche Rigon M, Mebazaa A, Zannad F, Alla F, Chevret S. Continuous positive airway pressure (CPAP) may not reduce short-term mortality in cardiogenic pulmonary edema: a propensity-based analysis. J Card Fail. 2013 Feb;19(2):108-16.
  • Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol. 2013 Jan 20;31(3):321-7.
  • Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7.
  • Zohar S, Resche-Rigon M, Chevret S. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clin Trials. 2013;10(3):414-21.
  • Plantaz D, Robert A, Thomas C, Desseaux K, Chevret S, Baruchel A. French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Exp Hematol Oncol. 2012 Dec 10;1(1):39.
  • Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel G, Schmitt C, Lejars O, Schneider P, Demeocq F, Bader-Meunier B, Bernaudin F, Perel Y, Auclerc MF, Cayuela JM, Leverger G, Baruchel A; FRALLE Group. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica. 2012 Nov;97(11):1743-50.
  • Redondo YT, Lambert J, Chevret S. A minimal net reclassification improvement to assess predictions of intensive care mortality. Stat Methods Med Res. 2012 Oct 14.
  • Tazi A, Marc K, Dominique S, de Bazelaire C, Crestani B, Chinet T, Israel-Biet D, Cadranel J, Frija J, Lorillon G, Valeyre D, Chevret S. Serial computed tomography and lung function testing in pulmonary Langerhans' cell histiocytosis. Eur Respir J. 2012 Oct;40(4):905-12.
  • Resche-Rigon M, Pirracchio R, Robin M, De Latour RP, Sibon D, Ades L, Ribaud P, Fermand JP, Thieblemont C, Socié G, Chevret S. Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases. BMC Blood Disord.2012 Aug 16;12:10.
  • Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):214-21.
  • Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10.
  • Pirracchio R, Resche-Rigon M, Chevret S. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. BMC Med Res Methodol. 2012 May 30;12:70.
  • Chevret S. Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med. 2012 May 20;31(11-12):1002-13.
  • Masserot-Lureau C, Adoui N, Degos F, de Bazelaire C, Soulier J, Chevret S, Socié G, Leblanc T. Incidence of liver abnormalities in Fanconi anemia patients. Am J Hematol. 2012 May;87(5):547-9.
  • Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia(ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012 Apr 21;379(9825):1508-16.
  • Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012 Mar 8;119(10):2228-33.
  • Taïeb O, Chevret S, Moro MR, Weiss MG, Biadi-Imhof A, Reyre A, Baubet T. Impact of migration on explanatory models of illness and addiction severity in patients with drug dependence in a Paris suburb. Subst Use Misuse. 2012 Mar;47(4):347-55.
  • Adès L, Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Bresler AG, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica. 2012 Feb;97(2):213-8.
  • Pichereau C, Desseaux K, Janin A, Scieux C, Peffault de Latour R, Xhaard A, Robin M, Ribaud P, Agbalika F, Chevret S, Socié G. The complex relationship between human herpesvirus 6 and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2012 Jan;18(1):141-4.
  • Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase ½ study of the acute leukemia French association. Am J Hematol. 2012 Jan;87(1):62-5.
  • Annane D, Antona M, Lehmann B, Kedzia C, Chevret S; CORTIFLU Investigators;CRICs; AZUREA; REVA/SRLF networks. Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic. Intensive Care Med. 2012 Jan;38(1):29-39.
  • Pirracchio R, Sprung CL, Payen D, Chevret S. Utility of time-dependent inverse-probability-of-treatment weights to analyze observational cohorts in the intensive care unit. J Clin Epidemiol. 2011 Dec;64(12):1373-82.
  • Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P, Ollivier I, Vinel JP, Mathurin P, Bronowicki JP, Vilgrain V, N'Kontchou G, Beaugrand M, Chevret S; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011 Dec;54(6):1987-97.
  • Moreno R, Sprung CL, Annane D, Chevret S, Briegel J, Keh D, Singer M, Weiss YG, Payen D, Cuthbertson BH, Vincent JL. Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study. Intensive Care Med. 2011 Nov;37(11):1765-72.
  • Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011 Oct 10;29(29):3907-13.
  • Timsit JF, Zahar JR, Chevret S. Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care. 2011 Oct;17(5):464-71.
  • Pirracchio R, Sprung C, Payen D, Chevret S. Benefits of ICU admission in critically ill patients: whether instrumental variable methods or propensity scores should be used. BMC Med Res Methodol. 2011 Sep 21;11:132.
  • Seegers V, Chevret S, Resche-Rigon M. Dose-finding design driven by efficacy in onco-hematology phase I/II trials. Stat Med. 2011 Jun 15;30(13):1574-83.
  • Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, Leprêtre S, Eghbali H, Van Den Neste E, Michallet M, Maloisel F, Bouabdallah K, Decaudin D, Berthou C, Brice P, Gonzalez H, Chapiro E, Radford-Weiss I, Leporrier N, Maloum K, Nguyen-Khac F, Davi F, Lejeune J, Merle-Béral H, Leporrier M. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011 Jun 9;117(23):6109-19.
  • Peigne V, Chaize M, Falissard B, Kentish-Barnes N, Rusinova K, Megarbane B, Bele N, Cariou A, Fieux F, Garrouste-Orgeas M, Georges H, Jourdain M, Kouatchet A, Lautrette A, Legriel S, Regnier B, Renault A, Thirion M, Timsit JF, Toledano D, Chevret S, Pochard F, Schlemmer B, Azoulay E. Important questions asked by family members of intensive care unit patients. Crit Care Med. 2011 Jun;39(6):1365-71.
  • Pibouleau L, Chevret S. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. J Clin Epidemiol. 2011 Mar;64(3):270-9.
  • Annane D, Chadda K, Gajdos P, Jars-Guincestre MC, Chevret S, Raphael JC. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med. 2011 Mar;37(3):486-92.
  • Karlin L, Arnulf B, Chevret S, Ades L, Robin M, De Latour RP, Malphettes M, Kabbara N, Asli B, Rocha V, Fermand JP, Socie G. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy. Bone Marrow Transplant. 2011 Feb;46(2):250-6.
  • Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Coïc L, Leveillé E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galactéros F, Torres M, Kuentz M, Ferry C, Socié G, Reinert P, Delacourt C. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011 Jan 27;117(4):1130-40.
  • de Miranda S, Pochard F, Chaize M, Megarbane B, Cuvelier A, Bele N, Gonzalez-Bermejo J, Aboab J, Lautrette A, Lemiale V, Roche N, Thirion M, Chevret S, Schlemmer B, Similowski T, Azoulay E. Postintensive care unit psychological burden in patients with chronic obstructive pulmonary disease and informal caregivers: A multicenter study. Crit Care Med. 2011 Jan;39(1):112-8.
  • Journot V, Pignon JP, Gaultier C, Daurat V, Bouxin-Métro A, Giraudeau B, Preux PM, Tréluyer JM, Chevret S, Plättner V, Thalamas C, Clisant S, Ravaud P, Chêne G; Optimon Collaborative Group. Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies—the Pre-Optimon study. Contemp Clin Trials. 2011 Jan;32(1):16-24.
  • Resche-Rigon M, S Zohar, Chevret S. Maximum-relevance weighted likelihood estimator: Application to the continual reassessment method. Statistics and its interface 2010; 3 (2):. 177-184
  • Deslandes E, Chevret S. Joint modeling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data. BMC Med Res Methodol. 2010 Jul 29;10:69.
  • Hiance A, Chevret S, Lévy V. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. J Clin Epidemiol.2009 Apr;62(4):431-437.
  • Katsahian S, Latouche A, Mary JY, Chevret S, Porcher R. Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemp Clin Trials. 2008 Mar;29(2):220-30.
  • Deslandes E, Chevret S. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia.Stat Med . 2007 30 déc; 26 (30) :5411-21